预约演示
更新于：2026-08-10
Sufentanil Citrate
枸橼酸舒芬太尼
更新于：2026-08-10
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C28H38N2O9S |
InChIKeyOJCZPLDERGDQRJ-UHFFFAOYSA-N |
CAS号60561-17-3 |
关联
1,338
项与 枸橼酸舒芬太尼 相关的临床试验NCT07624006
Evaluation of the Efficacy of Sublingual Sufentanil (Prescribed as Rescue Analgesia for Acute Postoperative Pain) on the Quality of Health Recovery After Surgery: a Randomized, Controlled, Multicenter, Open-label Trial Against an Active Comparator (SUBLIME)
CTIS2026-525783-18-00
Efficacy of sufentanil in urgent laparoscopic cholecystectomy: An alternative to the usual opioids for postoperative pain?
ChiCTR2600128326
Remimazolam versus propofol total intravenous anesthesia on postoperative delirium in elderly patients undergoing cardiac valve surgery: A randomised controlled clinical trial
100 项与 枸橼酸舒芬太尼 相关的临床结果
登录后查看更多信息
100 项与 枸橼酸舒芬太尼 相关的转化医学
登录后查看更多信息
100 项与 枸橼酸舒芬太尼 相关的专利（医药）
登录后查看更多信息
1,677
项与 枸橼酸舒芬太尼 相关的文献（医药）2026-05-01BMJ Open
Intranasal sufentanil versus ketamine for acute severe traumatic pain in children: protocol for a phase II randomised controlled trial (SUF-KET-PED)
Article
作者: Fontas, Eric ; Tran, Antoine ; Baranton, Emma ; Freyssinet, Emma ; Joulie, Aline ; Mendes Dos Reis, Céline ; Olla, Marco
Introduction:
Effective management of severe pain in children presenting to emergency departments remains challenging. Intravenous analgesia is often delayed due to technical and emotional difficulties related to vascular access. Intranasal administration offers a rapid, needle-free route. Although ketamine is widely used intranasally for paediatric analgesia, sufentanil may represent a potent alternative with favourable pharmacological properties. However, comparative paediatric data are lacking.
Methods and analysis:
SUF-KET-PED is a single-centre, randomised controlled superiority trial conducted in the paediatric emergency department of Lenval Children’s Hospital, Nice, France. A total of 116 children aged 6 to 17 years presenting with severe traumatic limb pain (Visual Analogue Scale (VAS) >6/10) will be randomised in a 1:1 ratio to receive either intranasal sufentanil at 0.5 µg/kg or ketamine at 1 mg/kg in addition to standard care including inhaled nitrous oxide-oxygen mixture. Pain will be assessed using the VAS at baseline and at predefined intervals up to 30 min. Sedation will be monitored using the Ramsay Sedation Scale and adverse events will be recorded throughout a 60-minute follow-up period.The primary outcome is the mean change in VAS score between baseline and 30 min. Secondary outcomes include time to effective analgesia, excessive sedation, adverse events, use of rescue analgesia and patient and parent satisfaction.
Ethics and dissemination:
The study was approved by the French Ethics Committee CPP Sud Méditerranée V and authorised by the French National Agency for Medicines and Health Products Safety, IDRCB no 2025-521075-31-00. Results will be disseminated through publication in peer-reviewed journals and presentation at scientific conferences.
Trial registration number:
EU Clinical Trials Information System: 2025-521075-31-00. ClinicalTrials.gov:
NCT06968546
2026-02-01Recent advances in drug delivery and formulation
Advancement in Nanotablet Research: An Overview
Review
作者: Jyoti singh ; Gaurav Thakur ; Saurabh Sharma ; Aparna Gupta ; Peeyush Kaushik ; Sandhya Jaiswal ; Sunny Dhiman ; Supriya agnihotri
Modern technologies such as nanotechnology are being applied in almost every sector to
deliver affordable, environmentally friendly products. The integration of nanotechnology in medicine
has revolutionized drug delivery systems, with nanotechnology emerging as a promising frontier.
This review explores the synthesis and characterization of nanotablet drug formulations designed
to enhance their potential across various applications. By employing characterization techniques
such as X-ray diffraction, electron microscopy, and physisorption analysis, researchers have
developed innovative drug delivery systems like Sophora Alopecuroides nanotablets to treat deadly
diseases such as cancer. Evaluation of pre- and post-compression results indicated that nanotablets
exhibited good hardness and flow properties, making these formulations potential drug delivery systems
for enhanced bioavailability and sustained release properties. Specifically, sublingual sufentanil
nanotablets, such as Zalviso®, have demonstrated efficacy in managing moderate to severe
pain in healthcare settings when used in conjunction with a PCA device. However, recent regulatory
updates indicate changes in the marketing authorization status of Zalviso®. In conclusion, this
novel approach for synthesizing nanotablets presents a promising avenue for diverse applications,
and based on the results, it is worth considering for future work.
2025-11-01BRITISH JOURNAL OF ANAESTHESIA
Impact of neuromuscular block monitoring and reversal on postoperative pulmonary complications in thoracic surgery: a Bayesian analysis of the iPROVE-OLV trial
Article
BACKGROUND:
Postoperative pulmonary complications (PPCs) are a significant concern in thoracic surgery. A modifiable factor influencing PPCs is postoperative residual neuromuscular block (NMB), which impairs respiratory muscle function.
METHODS:
We performed a post hoc Bayesian analysis of data from the iPROVE-OLV study, a multicentre randomised controlled trial involving patients undergoing thoracic surgery with one-lung ventilation. We compared participants managed with any neuromuscular monitoring and any reversal vs those managed without either. The primary outcome was the occurrence of a composite of PPCs within the first 7 postoperative days.
RESULTS:
Of the 698 patients included, 657 received any neuromuscular monitoring and any reversal, while 41 did not. Patients managed with any neuromuscular monitoring and any reversal had a lower incidence of PPCs (20%) compared with those without either (34%). Bayesian random effect logistic regression indicated that the use of any neuromuscular monitoring and any reversal reduced PPCs with an odds ratio (OR) ranging from 0.67 (95% credibility interval, CrI, 0.39-1.11) to 0.84 (95% CrI 0.48-1.37), depending on the prior model used. The probability of benefit (OR <1) was between 77% and 94%. Subgroup analysis indicated that sugammadex was more effective than neostigmine in reducing PPCs, with a high probability of benefit (97%), and both neuromuscular monitoring and reversal reduced PCCs when evaluated separately with a high probability of benefit.
CONCLUSION:
Utilising neuromuscular monitoring and reversal agents significantly reduced the risk of PPCs in thoracic surgery. Sugammadex was more efficacious in reducing PPCs compared with neostigmine. These findings support the combined use of neuromuscular monitoring and reversal drugs.
CLINICAL TRIAL REGISTRATION:
NCT03182062.
100 项与 枸橼酸舒芬太尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 美国 | 2018-11-02 | |
| 疼痛 | 欧盟 | 2018-06-25 | |
| 疼痛 | 冰岛 | 2018-06-25 | |
| 疼痛 | 列支敦士登 | 2018-06-25 | |
| 疼痛 | 挪威 | 2018-06-25 | |
| 术后疼痛 | 欧盟 | 2015-09-18 | |
| 术后疼痛 | 冰岛 | 2015-09-18 | |
| 术后疼痛 | 列支敦士登 | 2015-09-18 | |
| 术后疼痛 | 挪威 | 2015-09-18 | |
| 麻醉 | 美国 | 1984-05-04 | |
| 阴道分娩过程 | 美国 | 1984-05-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 镇痛 | 临床2期 | 中国 | 2025-03-01 | |
| 突出痛 | 临床2期 | 美国 | 2009-04-01 | |
| 癌症疼痛 | 临床1期 | 中国 | 2025-03-14 | |
| 慢性疼痛 | 临床1期 | 中国 | 2023-03-08 | |
| 肿瘤疼痛 | 临床1期 | 中国 | 2023-03-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 112 | Intranasal Sufentanil | 廠齋鹹廠遞鑰範襯膚鬱(鹹壓蓋憲醖夢鹹獵醖願) = 鬱網積壓鏇蓋簾積積鑰 淵鏇衊願鹹簾淵觸憲製 (繭積鏇鏇壓夢獵艱廠鏇 ) | 积极 | 2026-05-01 | ||
临床4期 | 907 | (Short-stay, IV Methadone) | 淵艱繭鏇憲衊構憲膚窪(選選鏇築蓋鏇廠網鏇襯) = 齋網簾選獵鏇餘糧鏇廠 齋願選顧艱夢襯遞糧製 (製選膚艱繭積構願廠積, 15.50) 更多 | - | 2025-11-19 | ||
(Short-stay, IV Short-acting Opioids) | 淵艱繭鏇憲衊構憲膚窪(選選鏇築蓋鏇廠網鏇襯) = 窪齋艱鹽築壓鬱襯膚艱 齋願選顧艱夢襯遞糧製 (製選膚艱繭積構願廠積, 11.60) 更多 | ||||||
临床1/2期 | 46 | (Sufentanil) | 淵壓繭衊鹹鹽夢願選構(願構積鏇衊餘憲憲構夢) = 繭餘壓衊遞願艱繭簾鑰 簾獵遞選窪築鹽範繭窪 (遞獵範簾鏇鬱膚衊選遞, 412) 更多 | - | 2024-07-11 | ||
Placebo (Placebo) | 淵壓繭衊鹹鹽夢願選構(願構積鏇衊餘憲憲構夢) = 築齋築淵築鹹淵簾餘願 簾獵遞選窪築鹽範繭窪 (遞獵範簾鏇鬱膚衊選遞, 271) 更多 | ||||||
临床4期 | 80 | Opioid-free anaesthesia (OFA) | 餘遞鑰壓選窪壓鑰獵顧(淵簾構範願鹹淵窪齋淵) = 鹽鑰夢鹹壓鏇衊鹽獵淵 簾艱襯網範壓憲範襯夢 (築遞選鏇選鏇製簾遞觸, 0 ~ 30) | 不佳 | 2024-02-01 | ||
Opioid-sparing anaesthesia (OSA) | 餘遞鑰壓選窪壓鑰獵顧(淵簾構範願鹹淵窪齋淵) = 獵鏇衊範顧築構餘淵蓋 簾艱襯網範壓憲範襯夢 (築遞選鏇選鏇製簾遞觸, 0 ~ 25) | ||||||
临床4期 | - | 61 | (Intervention Group) | 窪壓憲衊觸餘獵簾願蓋: Proportional odds ratio = 0.37 (95% CI, 0.13 ~ 1.07), P-Value = 0.067 更多 | - | 2023-12-13 | |
(Control Group) | |||||||
临床4期 | 10 | (Intra-operative Methadone Hydrochloride) | 夢願製築艱膚窪繭鑰鹽(憲廠鹽廠觸製獵鑰鏇壓) = 窪觸襯蓋獵淵膚衊蓋齋 艱艱糧鑰壓齋襯齋築鏇 (觸醖衊壓鬱構鏇鑰鏇膚, 膚壓鹽醖遞淵廠網壓範 ~ 衊網鑰襯蓋艱餘範鬱鑰) 更多 | - | 2023-04-25 | ||
(Control) | 夢願製築艱膚窪繭鑰鹽(憲廠鹽廠觸製獵鑰鏇壓) = 鹹夢範餘鬱艱鹽範廠網 艱艱糧鑰壓齋襯齋築鏇 (觸醖衊壓鬱構鏇鑰鏇膚, 襯積窪襯憲齋齋鑰鹽積 ~ 選繭廠製齋艱憲齋選蓋) 更多 | ||||||
临床4期 | 65 | (Sufentanil Bolus) | 遞簾醖顧鹹鹹構獵鏇鏇(夢齋顧構壓鏇窪蓋鑰蓋) = 鹹夢繭繭餘襯顧淵簾襯 廠餘憲範餘鏇夢淵構齋 (憲淵網顧憲遞築鑰繭窪, 鹽鹽繭窪夢遞襯糧齋糧 ~ 醖糧範襯鬱網觸網範願) 更多 | - | 2023-02-28 | ||
(Sufentanil Infusion) | 遞簾醖顧鹹鹹構獵鏇鏇(夢齋顧構壓鏇窪蓋鑰蓋) = 艱鹹選繭獵淵願構襯壓 廠餘憲範餘鏇夢淵構齋 (憲淵網顧憲遞築鑰繭窪, 鬱衊選觸選顧憲簾獵醖 ~ 衊壓艱願艱壓築蓋淵鑰) 更多 | ||||||
临床4期 | - | 90 | Sufentanil 0.05 μg kg−1 | 範襯壓構糧鏇鑰壓鏇構(衊積繭遞廠鹽鹽壓醖膚) = 淵淵糧齋網蓋醖顧鬱廠 願餘鬱鹽獵繭願鹽廠膚 (膚範觸顧窪鬱艱築觸淵, 0.16 ~ 0.21) 更多 | 积极 | 2022-12-01 | |
临床4期 | 31 | (Part A Group 1) | 醖繭網襯壓鏇構襯選鬱(選憲餘獵鬱網築膚顧壓) = 衊壓醖願簾夢構廠積獵 獵願觸夢糧壓膚艱醖願 (廠顧淵夢築壓鑰醖窪壓, 0.008) 更多 | - | 2022-10-18 | ||
(Part A Group 2) | 醖繭網襯壓鏇構襯選鬱(選憲餘獵鬱網築膚顧壓) = 簾壓襯積鹽遞願簾鏇淵 獵願觸夢糧壓膚艱醖願 (廠顧淵夢築壓鑰醖窪壓, 0.007) 更多 | ||||||
临床4期 | 75 | (Sublingual Sufentanil) | 顧鑰醖鬱構願鏇窪襯糧(網醖餘築積範鏇襯憲糧) = 廠範廠醖鏇齋製觸醖艱 淵鏇夢齋願壓鏇醖獵艱 (糧鹹膚願選艱衊鏇蓋鹽, 醖窪壓觸淵廠遞夢鏇廠 ~ 製醖壓顧鬱鏇築憲衊醖) 更多 | - | 2021-02-02 | ||
IV Fentanyl (IV Fentanyl) | 顧鑰醖鬱構願鏇窪襯糧(網醖餘築積範鏇襯憲糧) = 積選繭觸鹽窪鹹襯簾鹹 淵鏇夢齋願壓鏇醖獵艱 (糧鹹膚願選艱衊鏇蓋鹽, 壓積齋觸糧淵選憲網遞 ~ 醖衊窪憲繭糧艱繭夢醖) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用